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Abstract: 
Multiple lines of evidence suggest that the physiologically normal levels of low-
density lipoprotein cholesterol (LDL-C) and the thresholds for development of 
atherosclerosis and adverse coronary events are in the 30 to 70 mg/dL range. More 
patients have been studied in randomized controlled trials assessing the effects of 
statins on outcomes than any other drug class in the history of medicine. This 
cumulative body of evidence documents that atherosclerosis progression is halted and 
coronary heart disease (CHD) events are minimized when statin therapy with or without 
ezetimibe and, possibly proprotein convertase subtilisin–kexin type 9 (PCSK9) 
inhibitors, are utilized to drive down the LDL-C to a range of about 30 to 50 mg/dL. Thus 
far, these agents appear to be safe even when LDL-C is lowered to about 50 mg/dL; 
although more robust outcome and safety data are required, particularly for the PCSK9 
inhibitors and very low LDL-C levels (e.g. down to 25 mg/dL). In conclusion, the current 
national guidelines specifying only the use of a high-potency statin without specific LDL-
C goals may lead to substantial under treatment of high-risk individuals, leaving them 
vulnerable to future adverse cardiovascular (CV) events.  
  
Key Words: cholesterol, LDL, atherosclerosis, coronary disease, PCSK9 inhibitors, 
statins, ezetimibe, evolocumab, alirocumab. 
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Introduction:  
Forty percent of Americans show evidence for arterial plaque development by 50 
years of age.1 Despite cholesterol levels trending down in recent decades 
atherosclerosis remains endemic in part because about one-third, or 73 million adults in 
the US still have low-density lipoprotein cholesterol (LDL-C) levels above ideal.2,3 
Although LDL-C levels of about 30 to 70 mg/dL may seem unreasonably low by modern 
US standards, they are squarely in normal range for humans and other mammals eating 
the diet and living the lifestyle for which we are genetically adapted (Figure 1).2,3   
Indeed, even among those who are heterozygotes for two inactivating mutations in the 
proprotein convertase subtilisin–kexin type 9 (PCSK9) gene, causing strikingly low 
levels of LDL-C (mean = 14 mg/dL) there appears to be no harmful effects.4  
Furthermore, mendelian randomization analysis indicates having a lifelong very low 
LDL-C is associated with a very low risk of coronary heart disease (CHD).5 Thus, it 
appears that having very low LDL-C levels throughout life markedly reduces 
atherosclerosis development is compatible with otherwise normal health. Furthermore, 
there is good evidence that dramatic LDL-C lowering via lipoprotein apheresis improves 
cardiovascular (CV) morbidity and life expectancy in familial hypercholesterolemia.6  
 
LDL-C: Obligate Precursor to Atherosclerosis 
 
Among the myriad CV risk factors that contribute to the genesis and progression 
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of arterial atherosclerosis, the LDL-C level is among the most critical. LDL-C penetrates 
the intima whereby Apo B binds to proteoglycans leading to oxidized LDL-C, which 
incites inflammation, endothelial dysfunction, and atherosclerosis.7 Severe elevations of 
LDL-C levels (> 190 mg/dL) are strongly associated with CHD risk; however 
atherosclerosis and its complications are common even for those with LDL-C levels of 
90 to 130 mg/dL.8 Furthermore, individuals in the top decile of LDL-C levels account for 
just 20% of the CHD events.8 Thus, restricting therapy to only on those with severely 
elevated LDL-C levels will ignore about 4 out of every 5 people destined to suffer an 
adverse CV event.2,8 
 
The numerous randomized controlled trials using statins have documented 
significant reductions in CHD events and all-cause mortality, especially among 
secondary prevention populations.2,8-10 Most individuals in these trials had baseline 
LDL-C levels from 110 to 180 mg/dL, with on-treatment LDL-C levels ranging between 
55 and 120 mg/dL.2,9  Statin-induced LDL-C reductions of 25 to 50% caused 
corresponding drops in adverse CV events of about 20 to 44%.2,8-10  Despite these 
impressive reductions in risk, the majority of CHD events continued to occur. High-risk 
individuals such as those with established CV disease, diabetes or familial 
hypercholesterolemia may have a substantial residual risk for future adverse CV events 
even while being treated with a high-potency statin. Theoretically, this residual risk in 
secondary prevention may be significantly attenuated by therapies that can safely and 
effectively drive LDL-C levels down into the 30-to 70-mg/dL range. Indeed, newer 
agents such as the PCSK9 inhibitors and ezetimibe, when added to baseline statin 
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therapy impart more robust reductions in LDL-C, and may possibly further improve CV 
outcomes.11-14 A very large meta-analysis of RCTs reported that using statins to drive 
LDL-C down to very low levels is safe and effective, with further CV risk reduction 
beyond the benefits noted with moderate LDL-C lowering (Figure 2).11 
 
Current Guidelines’ Recommendations 
 
The most recent iteration of the ACC/AHA Guideline on the Treatment of Blood 
Cholesterol to Reduce Atherosclerotic CV Risk in Adults eliminated specific treatment 
goals15 stating there was no evidence of CV benefit in treating to a specific LDL-C 
target. Unfortunately, this statement ignores the fact that hundreds of thousands of 
patients have been studied in randomized controlled trials showing that statins with or 
without ezetimibe lower risk of CHD events in proportion to their ability to lower LDL-C, 
particularly in the setting of secondary prevention. Although the current AHA/ACC 
guidelines are practical and more affordable from a public health standpoint, other 
consensus expert guidelines including the National Lipid Association, the European 
Society of Cardiology, and the European Atherosclerosis Society guidelines have 
continued to re-affirm the importance of LDL-C as the primary target for treatment, citing 
goals of < 100 mg/dL for high-risk individuals, with an option to treat very high-risk 
patients to less than 70 mg/dL.16    
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 High-density lipoprotein cholesterol (HDL-C) is not recommended as a target for 
treatment.16  Although HDL-C is an important risk factor and should be used in risk 
calculation, it has not been found to be useful as a target for pharmacological therapy.16 
Multiple large and definitive studies show that despite significant improvement in HDL-C 
levels, niacin, fibrates and the cholesterol ester transfer protein inhibitors do not 
significantly reduce adverse outcomes (and on the balance may cause more harm than 
benefit).17,18 Non-HDL cholesterol , and/or Apo B levels are considered as important 
lipid targets by many lipid experts; and these parameters may be particularly relevant 
for individuals with elevated triglycerides, diabetes, metabolic syndrome, or chronic 
kidney disease.16  
 
Preventing Atherosclerosis and Adverse Coronary Events 
 
When examined in aggregate, the randomized trials using statins reveal a 
continuous direct association between on-treatment LDL-C and risk of CHD events, 
without any specific threshold where lower LDL-C levels are not correlated with lower 
risk.19  Both primary prevention and secondary prevention trials show this relationship, 
though it is much stronger in the setting of secondary prevention where event rates are 
much higher (Figure 3a and 3b).16 Of particular interest, the LDL-C threshold at which 
the CV event rate is extrapolated to approach zero is about 55 mg/dL for primary 
prevention and 30 mg/dL for secondary prevention. This massive body of evidence 
based on very high quality data from randomized controlled trials implicates LDL-C as 
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the requisite catalyst in the atherosclerosis process wherein very low LDL-C levels may 
minimize the rate of CHD events despite an otherwise ominous CV risk factor profile.   
 
Evidence from randomized controlled trials also clearly documents a highly 
significant direct relationship between on-treatment LDL-C level and atherosclerotic 
progression rate.2 The cumulative body of data indicates that when patients are on 
therapy with a statin, ezetimibe, and/or a PCSK9 inhibitor, the atherosclerosis 
progression/regression rate as quantified by the intravascular coronary ultrasound is 
closely related to the chronic LDL-C level (Figure 4).20,21 
 
LDL-lowering Drugs: Which Ones Improve Cardiovascular Outcomes?  
 
Throughout the entire history of medicine and pharmacology, no drug class has 
been so thoroughly tested in large randomized controlled trials as have the statins. As 
outlined above, in aggregate this database of statin trials reveals highly significant 
inverse relationships between on-statin LDL-C levels and: a) progression coronary 
atherosclerosis, and b) risk of major adverse CV events. Despite the availability of high-
potency statins (most of which are now available as inexpensive generics), up to half of 
patients with CHD or at high risk due to issues such as diabetes, subclinical CHD 
(documented by asymptomatic coronary artery calcification) and familial 
hypercholesterolemia are not treated to an LDL-C of 70 mg/dL.11,22 A substantial portion 
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of this ongoing future risk of CV events might be mitigated by more aggressive LDL-C 
reduction. Ezetimibe, a cholesterol-absorption inhibitor, has recently also proven to be 
effective for lowering LDL-C and modestly reducing major CV events.12 The IMPROVE-
IT was a large randomized trial in which ezetimibe when added to a statin significantly 
lowered on-treatment LDL-C from 70 to 54 mg/dL, with a concomitant statistically 
significant reduction in adverse CV events compared to the statin alone.23  
 
Several large randomized controlled trials using drugs such as high-dose oral 
equine estrogens, niacin, fibrates, and CETP inhibitors have each lowered LDL-C levels 
but failed to improve CV outcomes in randomized controlled trials.24  These agents not 
coincidentally have common serious adverse effects, in addition to their LDL-lowering 
actions. Lipid modifying drugs are medications that must be taken for years to decades; 
serious off-target adverse effects can tilt the risk/benefit ratio so that on the balance the 
agents do not improve prognosis despite improving the lipid profile. 
 
PCSK9 Inhibitors 
 
Evolocumab and alirocumab are monoclonal antibodies that inhibit PCSK9. 
These two PCSK9 inhibitors are both administered via subcutaneous injections twice 
per month. Evolocumab and alirocumab each reduce LDL levels approximately 45 to 
70% beyond what can be achieved with maximally tolerated statin +/- ezetimibe 
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therapy.25,26  When PCSK9 inhibitors are used with statins +/- ezetimibe for baseline 
therapy, about 90% of individuals are able to achieve LDL levels under 70 mg/dL; 
compared to only 50% of individuals on high-potency statin +/- ezetimibe.12-14  
 
These PCSK9 inhibitors share with statins the ability to increase LDL receptor 
activity on the surface of the hepatocyte. However, because statins markedly up-
regulate the production of PCSK9, the use of a PCSK9 inhibitor with a statin will provide 
synergistic reductions in LDL-C.12-14,27   Support for the premise that PCSK9 inhibition 
may reduce improve outcomes comes from the observation that loss-of-function genetic 
variants leading to reductions in PCSK9 activity have been linked to a significantly 
reduced lifetime risk for adverse CV events.5,22 Two recently published post hoc 
analyses, which comprise only preliminary and exploratory data, suggest that PCSK9 
inhibitors may have the potential to reduce adverse CV events (Figure 5 and Figure 
6).13,14 Both evolocumab and alirocumab lowered LDL-C levels by approximately 61%, 
from baseline on-statin levels of about 120 mg/dL down to 48 mg/dL.  
 
In their pre-release development programs, evolocumab and alirocumab were 
able to drive LDL-C levels below 25 mg/dL in 37% and 24% of patients respectively.  
Thus, we will have soon have unprecedented data regarding the potential benefits 
versus harms of treating to very low LDL-C levels. Evolocumab and alirocumab are both 
being studied in very large clinical CV event reduction trials, which are expected to 
report results in 2017.28  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
10 
 
 
The recently published Glascov trial randomized 968 patients with coronary 
disease to evolocumab + statin versus placebo + statin. Intravascular ultrasound of the 
coronary arteries was performed at baseline and 18 months later at study end. The 
course of evolocumab therapy met both its primary endpoint (change in percent 
atheroma volume (PAV) compared with placebo, and the secondary endpoint—
atheroma regression compared to placebo.21  
 
Potential Dangers of Very Low LDL-C 
 
Cholesterol is an obligate precursor for synthesis of steroid hormones, vitamin D, 
and bile acids, and is also an essential component of all cell membranes. Accordingly, it 
is probable that an ideal range of blood cholesterol exists above and below which 
adverse health consequences might be anticipated. Chronic serious illnesses, including 
cancer, gastrointestinal diseases, infections and neurological/psychological disorders 
are often associated with depressed LDL-C levels as a result of malnutrition and/or 
cachexia. Although low cholesterol levels are often correlated with increased morbidity 
and mortality, especially among the elderly, the reduced lipid levels among these 
cohorts may occur as a result of, not the cause of disease.  
 
Epidemiologic studies show that people with lifelong low levels of LDL-C tend to 
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have excellent life expectancy.5,29  The cumulative body of data with statins indicates 
substantial CV benefits that are directly proportional to LDL-C lowering with no increase 
in adverse events such as cancer or non-CV mortality.2,9  The incidence of the two most 
frequently reported adverse effects attributed to statins—muscle/joint pain, and 
abnormal liver function tests—rise modestly as a function of statin doses but are 
unrelated to the on-treatment LDL-C levels achieved.9  Although subjective statin-
related side effects such as myalgias, fatigue, and loss of mental acuity are common, 
statin intolerance is markedly over-diagnosed both by patients (via the nocebo effect) 
and physicians.  For example, in blinded alirocumab studies, 60 to 70% of patients 
previously considered statin-intolerant were able to tolerate 20 mg of atorvastatin.13,24  
 
Individuals with heterozygous hypobetalipoproteinemia have lifelong total 
cholesterol levels in the range of 80 to 130 mg/dl with LDL-C levels of as low as 30 
mg/dL.  This heritable condition is generally characterized by excellent overall general 
health and above average life expectancy, owing to the absence of atherosclerosis and 
its complications.  A recently published study performed a series of meta-analyses 
involving over 300,000 people with nine polymorphisms in 6 different genes to evaluate 
the effects of genetically induced lifelong lower LDL-C levels on risk of CHD.5 This 
“Mendelian Randomization” natural experiment reported that LDL-C levels were strongly 
correlated with risk of CHD, suggesting that safe and effective LDL-lowering therapies 
are likely to be highly efficacious for the improving long term CV prognosis. (Figure 7).5  
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Figure Legends 
 
Figure 1: Comparative total cholesterol levels among various populations of humans 
and wild animals.2 
 
Figure 2: The x-axis represents achieved on-statin LDL-C levels. LDL C = low-density 
lipoprotein cholesterol; HR = hazard ratio. 
Statin LDL-C Levels and Risk for Major Cardiovascular Events. Distribution of achieved 
on-statin LDL-C levels (dark blue curve; right y-axis) and the risk of major 
cardiovascular events (light blue line; left y-axis).11 
 
Figure 3a: Relationship between on-treatment LDL-C levels and CHD events in studies 
of primary prevention. Pl = placebo; Rx = treatment.16 
 
Figure 3b: Relationship between on-treatment LDL-C levels and CHD events in studies 
of secondary prevention.16 
 
Figure 4: Relationship Between Achieved LDL-C Levels and the Median Change in 
Percent Atheroma Volume as documented by Intravascular Ultrasound Trials.20 
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Figure 5: Cumulative Incidence of Cardiovascular Events Evolocumab vs standard 
therapy.14 
 
Figure 6: Cumulative Incidence of Cardiovascular Events Alirocumab vs placebo 
therapy.13  
 
Figure 7: Boxes represent the proportional risk reduction (1 − OR) of CHD for each 
exposure allele plotted against the absolute magnitude of lower LDL-C associated with 
that allele (measured in mg/dl).5  
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
